501022-53-3

Upstream product

• 693222-15-0 [4-(4-benzyloxycarbonylamino-1-chloroacetyl-butylcarbamoyl)-4-tert-butoxycarbonylamino-butyl]-carbamic acid benzyl ester 
• 7733-29-1 Z-Orn(Boc)-OH 
• 1000290-81-2 H-Orn(Z)-CH₂Cl 
• 143139-11-1 Boc-Orn(Z)-CH₂Cl 
• 2480-93-5 Boc-Orn(Z)-OH 
• 649757-34-6 Boc-Orn(Z)-Orn(Z)-CH₂Cl 
• 359781-89-8 Boc-Orn(Cbz)-OH 
• 693222-11-6 (4-tert-butoxycarbonylamino-6-chloro-5-oxo-hexyl)-carbamic acid benzyl ester 
• 754185-59-6 (4-amino-6-chloro-5-oxo-hexyl)-carbamic acid benzyl ester 

Downstream Products

• 872043-68-0 C₆₃H₈₀N₈O₁₁ 
• 627535-19-7 3,6-bis[3'-N^α-Boc-(2',6'-dimethyl-L-tyrosine)aminopropyl]-5-methyl-2(1H)-pyrazinone 
• 627535-18-6 3,6-bis[3'-(N^α-Boc-Tyr)aminopropyl]-5-methyl-2(1H)-pyrazinone 

Relevant academic research and scientific papers

Potent Dmt-Tic pharmacophoric δ- and μ-opioid receptor antagonists

A series of dimeric Dmt-Tic (2′,6′-dimethyl-L-tyrosyl-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid) analogues (8-14, 18-22) were covalently linked through diaminoalkane and symmetric or asymmetric 3,6-diaminoalkyl-2(1H)-pyrazinone moieties. All the c

Studies on the mechanism of 1,2-dihydropyrazin-2-one ring formation from dipeptidyl chloromethyl ketone and its chemical properties: Immediate deamination during catalytic hydrogenation

1,2-Dihydropyrazin-2-one derivatives, which have two aminoalkyl groups at the positions 3 and 6, were found to be efficient tools for the construction of potent, selective and long-acting opioid mimetics. During the course of preparation, we found that the catalytic hydrogenation of 3,6- bis(benzyloxycarbonylaminomethyl)-5-methyl-1,2-dihydropyrazin-2-one to remove the benzyloxycarbonyl groups resulted in a side reaction. By MS and NMR studies and by preparation of additional 1,2-dihydropyrazin-2-one derivatives, the structure of the by-product was identified as 3-aminomethyl-5,6-dimethyl-1,2- dihydropyrazin-2-one. Preparation of additional compounds substituted with deuterium provided us with sufficient information to confirm the structure of the product and to support a cyclization mechanism in its formation.

Oral Bioavailability of a New Class of μ-Opioid Receptor Agonists Containing 3,6-Bis[Dmt-NH(CH2)n]-2(1H)-pyrazinone with Central-Mediated Analgesia

The inability of opioid peptides to be transported through epithelial membranes in the gastrointestinal tract and pass the blood-brain barrier limits their effectiveness for oral application in an antinociceptive treatment regime. To overcome this limitat

Immediate deamination from the aminomethyl group attached to 1,2-dihydropyrazin-2-one derivative during catalytic hydrogenation

The catalytic hydrogenation of 3,6-bis(benzyloxycarbonylaminomethyl)-5-methyl-1,2-dihydropyrazin-2-one to remove benzyloxycarbonyl (Z) groups resulted in a side reaction. Purification by reverse-phase HPLC and analysis by proton nuclear magnetic resonance